Obinutuzumab for chronic ITP that hasn't responded to steroids
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with ITP for at least 3 months.
- Your platelet count has been below 30 on two tests done at least one week apart in the last 2 weeks.
- Steroids (like prednisone) did not work for you or the effect stopped.
- You are not pregnant or nursing, and have no active infections or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.